Press Release
| April 30, 2018

Q2 Solutions Partners with NanoString to Market Digital Spatial Profiling Service

Morrisville, NC - April 30, 2018 – Q2 Solutions has recently partnered with NanoString Technologies to offer Digital Spatial Profiling (DSP) services to our customers through an early Technology Access Program (TAP) in advance of the expected commercial launch of NanoString’s DSP instrument platform in 2019.

NanoString's DSP technology enables precise and highly multiplexed quantification of protein and gene expression spatially resolved for regions of interest across heterogeneous tissue samples, aiding in the ability to define and redefine the patient population for a given therapy under development.

DSP technology is currently available for “research use only”, so Q2 Solutions is honored to be a conduit in bringing this technology forward to pharmaceutical clients in the context of clinical trials for the very first time. Leveraging this technology, in conjunction with our genomics know-how® and industry leading anatomic pathology expertise, will bring novel solutions to our clinical trial sponsors moving forward.

“We are committed to being an innovative, dedicated, and responsive partner to our clients and bringing cutting-edge technologies in key areas such as Immuno-Oncology. Aligning with this mission, our partnership with NanoString allows us to be an early adopter of a cutting-edge diagnostic technology and introduce it to our clients before it is commercially available. We are pleased to partner with NanoString as one of the first CROs with access to this technology”, said Patrice Hugo, Ph.D. Chief Scientific Officer at Q2 Solutions.

Biomarker assays, enabled by technologies like DSP from NanoString, play an important role in the drug development process as it helps identify patients more likely to respond to targeted drugs. Q2 Solutions helps customers simplify and align their biomarker and companion diagnostics strategies by providing solutions that speed development and increase the probability of regulatory and commercial success, ultimately delivering the right drug to the right patient at the right time.


About Q2 Solutions
Q2 Solutions is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q2 Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q2 Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities. To learn more, visit www.q2labsolutions.com.